Literature DB >> 5548035

Diagnosis of glycosphingolipidoses by urinary-sediment analysis.

R J Desnick, G Dawson, S J Desnick, C C Sweeley, W Krivit.   

Abstract

Mesh:

Substances:

Year:  1971        PMID: 5548035     DOI: 10.1056/NEJM197104082841401

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  12 in total

Review 1.  Basic findings and current developments in sphingolipidoses.

Authors:  H Pilz; R Heipertz; D Seidel
Journal:  Hum Genet       Date:  1979-03-12       Impact factor: 4.132

2.  Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA.

Authors:  Daniël Blom; Dave Speijer; Gabor E Linthorst; Wilma G Donker-Koopman; Anneke Strijland; Johannes M F G Aerts
Journal:  Am J Hum Genet       Date:  2002-12-06       Impact factor: 11.025

3.  I-cell disease (mucolipidosis II):a report on its pathology.

Authors:  J J Martin; J G Leroy; J P Farriaux; G Fontaine; R J Desnick; A Cabello
Journal:  Acta Neuropathol       Date:  1975-12-30       Impact factor: 17.088

4.  [Neurological symptoms in Fabry's disease. Report of a case with neuromuscular symptoms and review of the literature].

Authors:  H Pilz; E Volles; H A Paul; A Denden
Journal:  Z Neurol       Date:  1972

5.  Hepatic galactosylceramide in globoid cell leukodystrophy (Krabbe's disease).

Authors:  G Dawson
Journal:  Lipids       Date:  1973-03       Impact factor: 1.880

6.  Increased glycosphingolipid excretion associated with proteinuria.

Authors:  R R Townsend; R M Orth; C M Clawson; S C Li; Y T Li
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

7.  Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease.

Authors:  K Mills; P Morris; P Lee; A Vellodi; S Waldek; E Young; B Winchester
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

8.  Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease.

Authors:  Kevin Mills; Ashok Vellodi; Peter Morris; Donald Cooper; Michael Morris; Elisabeth Young; Bryan Winchester
Journal:  Eur J Pediatr       Date:  2004-10       Impact factor: 3.183

9.  Light- and electron-microscopic histochemistry of Fabry's disease.

Authors:  T Faraggiana; J Churg; E Grishman; L Strauss; A Prado; D F Bishop; E Schuchman; R J Desnick
Journal:  Am J Pathol       Date:  1981-05       Impact factor: 4.307

10.  Proposed high-risk screening protocol for Fabry disease in patients with renal and vascular disease.

Authors:  C Auray-Blais; D S Millington; S P Young; J T R Clarke; R Schiffmann
Journal:  J Inherit Metab Dis       Date:  2009-01-26       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.